Social Anxiety Disorder

American Psychiatric Association: Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Washington (DC): American Psychiatric Association; 2000.

Liebowitz MR Gorman JM Fyer AJ Klein DF . Social phobia. Review of a neglected anxiety disorder. Arch Gen Psychiatry 1985;42:729–36.

Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 2003;72(2):71–9.

Wittchen HU Fehm L. Epidemiology, patterns of comorbidity and associated disabilities of social phobia. Psychiatr Clin North Am 2001;24:617–41.

Kagan J Snidman N Zentner M Peterson E. Infant temperament and anxious symptoms in school age children. Dev Psychopathol 1999;11:209–24.

Chavira DA Stein MB Bailey K Stein MT . Child anxiety in primary care: Prevalent but untreated. Depress Anxiety 2004;20:155–64.

Wakefield JC Horwitz AV Schmitz MF . Are we overpathologizing the socially anxious? Social phobia from a harmful dysfunction perspective. Can J Psychiatry 2005;50:317–9.

Rowa K Antony MM . Psychological treatments for social phobia. Can J Psychiatry 2005 2005;50:308–16.

Stein DJ Ipser JC van Balkom AJ . Pharmacotherapy for social anxiety disorder. The Cochrane database of systematic reviews 2000, Issue 4. CD001206. DOI:10.1002/14651858.CD001206.pub2.

Stein DJ Kasper S Andersen EW Nil R Lader M. Escitalopram in the treatment of social anxiety disorder: Analysis of efficacy for different clinical subgroups and symptom dimensions. Depress Anxiety 2004;20:175–81.

Kasper S Stein DJ Loft H Nil R. Escitalopram in the treatment of social anxiety disorder: Randomized, placebo-controlled, flexible dosage study. Br J Psychiatry 2005;186:222–6.

Wagner KD Berard R Stein MB Wetherold E Carpenter DJ Perera P , and others. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 2004;61:1153–62.

Stein DJ Versiani M Hair T Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder. Arch Gen Psychiatry 2002;59:1111–8.

Leibowitz MR Mangano RM Bradwejn J Asnis G , SAD Study Group. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 2005;66:238–47.

Leibowitz MR Gelenberg AJ Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005;62:190–8.

Westenberg HG Stein DJ Yang H Li D Barbato LM . A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004;24:49–55.

Pande AC Feltner DE Jefferson JW Davidson JR Pollack M Stein MB , and others. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: A placebo-controlled, multicenter study. J Clin Psychopharmacol 2004;24:141–9.

Kobak KA Taylor LV Warner G Futterer R. St John's wort vs placebo in social phobia: Results from a placebo-controlled pilot study. J Clin Psychopharmacol 2005;25:51–8.

Van Ameringen M Mancini C Pipe B Oakman J Bennett M. An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry 2004;65:1674–8.

Fergusson D Doucette S Glass KC Shapiro S Healy D Hebert P , and others. Association between suicide attempts and selective serotonin reuptake inhibitors: Systematic review of randomised controlled trials. BMJ. 2005;330:396.